Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Public health ; 2023.
Article in English | EuropePMC | ID: covidwho-2260329

ABSTRACT

Objectives The aim of this study was to assess the frequency of indirect positive health outcomes as a result of the COVID-19 pandemic. Study design Systematic review. Methods Articles were identified from four online databases (Web of Science, Scopus, PubMed and Google Scholar) using predetermined search terms. After studies were systematically identified, the results were summarised narratively. The indirect positive health outcomes associated with the emergence of COVID-19 and measures taken for its prevention were categorised into four health dimensions (physical, mental, social and digital). Results After initial screening, 44 articles were assessed for eligibility and 33 were included in the final sample. Of the included studies, 72.73% noted a benefit from COVID-19 prevention measures in the physical health dimension. In addition, 12.12%, 9.09%, 3.03% and 3.03% of articles reported a positive impact in the digital, mental, social, and combined digital and mental health dimensions, respectively. Conclusions Despite the catastrophic health, socio-economic and political crises associated with the COVID-19 emergency, it has also resulted in some positive health outcomes. Reduced air pollutants, improved disease prevention practices, increased digital health delivery, and improved mental and social health dimensions were reported during the pandemic. Integrated and collaborative activities for the persistence of these health benefits are recommended. Graphical Image 1

2.
BMC Public Health ; 23(1): 334, 2023 02 15.
Article in English | MEDLINE | ID: covidwho-2260328

ABSTRACT

BACKGROUND: The emergence of COVID-19 has resulted in health, socio-economic, and political crises. The overall health impact of this disease can be measured by disability-adjusted life years (DALYs) which is the sum of the life years lost due to disability (YLDs) and the years life lost due to premature death (YLLs). The overarching objective of this systematic review was to identify the health burdens of COVID-19 and summarise the literature that can aid health regulators to make evidence-based decisions on COVID-19 mitigation strategies. METHODS: This systematic review was conducted using the PRISMA 2020 guidelines. DALYs-based primary studies were collected from databases, manual searches, and included studies' references. The primary studies published in English language, conducted since the emergence of COVID-19, and using DALYs or its subsets (years life lost due to disability and/or years life lost due to premature death) as health impact metrics, were the inclusion criteria. The combined disability and mortality health impact of COVID-19 was measured in DALYs. The risk of bias due to literature selection, identification, and reporting processes was assessed using the Joanna Bridges Institute critical appraisal tool for cross-sectional studies, and the certainty of evidence was assessed using the GRADE Pro tool. RESULT: Of the 1459 identified studies, twelve of them were eligible for inclusion in the review. The years life lost due to COVID-19 related mortality was dominant over the years life lost due to COVID-19 related disability (disability times from the onset of COVID-19 to recovery, from diseases occurrence to mortality, and the long-term consequences of COVID-19) in all included studies. The long-term consequence disability time and the pre-death disability time were not assessed by most of the reviewed articles. CONCLUSION: The impact of COVID-19 on both the length and quality of life has been substantial and has been causing considerable health crises worldwide. The health burden of COVID-19 was greater than other infectious diseases. Further studies focussing on issues examining increasing preparedness for future pandemics, public sensitization, and multi-sectorial integration are recommended.


Subject(s)
COVID-19 , Life Expectancy , Humans , Disability-Adjusted Life Years , Quality-Adjusted Life Years , COVID-19/epidemiology , Quality of Life , Cross-Sectional Studies , Global Health
4.
PLoS One ; 17(8): e0272859, 2022.
Article in English | MEDLINE | ID: covidwho-2079727

ABSTRACT

BACKGROUND: Food security is substantially affected directly by COVID-19 and/or indirectly by the measures adopted for the prevention of COVID-19 transmission. The aim of this systematic review is to summarize the impact of COVID-19 on food security and identify the most compromised food security dimension to ease the food security regulators and actors' intervention prioritisation. METHODOLOGY: Primary research focused on the impact of COVID-19 on food security will be searched from three online databases (PubMed, Web of Science, and Scopus), manually using a google scholar search engine, and studies' reference list were also manually searched. The prevalence of food insecurity in each study and the most compromised food security dimension including their associated factors will be identified. The food insecurity before and after COVID-19 emergence and the status of food security dimension before and after COVID-19 will be compared and interpreted. DISCUSSION: The heterogeneity of the studies and the factors for the variability of outcomes will be discussed. COVID-19 had a negative impact on food security if the food insecurity prevalence before the emergence of COVID-19 is less than during the COVID-19 pandemic. Other confounding factors that can contribute to the high food insecurity prevalence like natural disasters, war, and instability will be considered in addition to COVID-19. REGISTRATION: This systematic review protocol is registered in PROSPERO under the registration number: CRD42022325475.


Subject(s)
COVID-19 , Food Security , Food Supply , COVID-19/epidemiology , Humans , Pandemics , Prevalence , Systematic Reviews as Topic
5.
PLoS One ; 17(9): e0274468, 2022.
Article in English | MEDLINE | ID: covidwho-2021972

ABSTRACT

BACKGROUND: COVID-19 is a highly contagious infectious disease that emerged in 2019. This disease is causing devastating health, socio-economic, and economic crises. More specifically COVID-19 is affecting both the quality and length of human life. The overall health impact of this disease is measured by the disability-adjusted life years which is the sum of the life years lost due to disability (the effect on the health quality) and the years life lost due to premature death (effect on the length of life). The purpose of this review is to summarise DALYs-based health impact publications and produce compiled and informative literature that can aid the health regulators to make evidence-based decisions on mitigating COVID-19. METHODS: The review will be conducted using the PRISMA 2020 guidelines. The DALYs-based original observational and cross-sectional studies will be collected for assessing the health impact of COVID-19. Both the life quality and length impacts of COVID-19 will be reviewed. The life quality impact of COVID-19 will be measured using the life years lost due to disability (pre-recovery illness, pre-death illness, and post-acute consequences), and its impact on the length of life will be measured with years of life lost due to premature death (shortening of life expectancy). The combined health impact of COVID-19 on the quality and length of life will be measured in disability-adjusted life years. DISCUSSION: The impacts of COVID-19 on the two health outcomes (quality and length of life) will indicate the level of COVID-19 health burden. The increase or decrease of COVID-19 health impact might be due to the sample size differences of different studies and the omission of years lost due to post-acute consequences in some studies. After having a summarized systematic review health decision-makers will apply an impact-based response to COVID-19. TRAIL REGISTRATION: Systematic review registration: This protocol is pre-registered in PROSPERO with the registration number CRD42022324931.


Subject(s)
COVID-19 , Disabled Persons , COVID-19/epidemiology , Cross-Sectional Studies , Disability-Adjusted Life Years , Humans , Quality-Adjusted Life Years , Review Literature as Topic , Systematic Reviews as Topic
6.
Water ; 14(12):1924, 2022.
Article in English | ProQuest Central | ID: covidwho-1911740

ABSTRACT

The present study analyzes the market access of the biggest fish market at Chattogram coastal region of Bangladesh affected by COVID-19. The food chain was reduced locally, regionally, and globally as supply chains were disturbed and international seafood exports were halted for a certain period. For data collection several qualitative data collection tools, such as individual interviews as well as secondary document analysis were employed. To realize the overarching aim of this research the whole market system was analyzed including the supplier, wholesaler, retailer, as well as the consumer of the domestic market in the Chattogram district. The result shows that the pandemic slowed the supply and demand in the domestic fish market, and as a consequence the price of fish was distinctly reduced in the whole market system. The result highlights that the most affected stages of the supply chains are the supply quantity, the interval of the supply, and the quantity of fish sales. Furthermore, the principally affected stages of the demand chains are consumer demand and alternation in the preference of the consumer. To overcome such situation, this study recommends governmental financial support to trades to ensure the smooth flow of the supply and demand and create an alternative market system for the consumer. The pandemic and the measures to address the pandemic have created significant new challenges for market access and controlling pricing in domestic markets. Regularly engage of the policymakers are thus the prerequisite to overcome the compensation of trades and ensure food security in this sector.

7.
Results in Control and Optimization ; : 100119, 2022.
Article in English | ScienceDirect | ID: covidwho-1773729

ABSTRACT

COVID-19 takes a gigantic form worldwide in a short time from December, 2019. For this reason, World Health Organization (WHO) declared COVID-19 as a pandemic outbreak. In the early days when this outbreak began, the coronavirus spread rapidly in the community due to a lack of knowledge about the virus and the unavailability of medical facilities. Therefore it becomes a significant challenge to control the influence of the disease outbreak. In this situation, mathematical models are an important tool to employ an effective strategy in order to fight against this pandemic. To study the disease dynamics and their influence among the people, we propose a deterministic mathematical model for the COVID-19 outbreak and validate the model with real data of Italy from 15th Feb 2020 to 14th July 2020. We establish the positivity and boundedness of solutions, local stability of equilibria to examine its epidemiological relevance. Sensitivity analysis has been performed to identify the highly influential parameters which have the most impact on basic reproduction number (R0). We estimate the basic reproduction number (R0) from available data in Italy and also study effective reproduction numbers based on reported data per day from 15th Feb 2020 to 14th July 2020 in Italy. Finally, the disease control policy has been summarized in the conclusion section.

8.
J Med Virol ; 94(4): 1336-1349, 2022 04.
Article in English | MEDLINE | ID: covidwho-1718399

ABSTRACT

The entire world has been suffering from the coronavirus disease 2019 (COVID-19) pandemic since March 11, 2020. More than a year later, the COVID-19 vaccination brought hope to control this viral pandemic. Here, we review the unknowns of the COVID-19 vaccination, such as its longevity, asymptomatic spread, long-term side effects, and its efficacy on immunocompromised patients. In addition, we discuss challenges associated with the COVID-19 vaccination, such as the global access and distribution of vaccine doses, adherence to hygiene guidelines after vaccination, the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, and vaccine resistance. Despite all these challenges and the fact that the end of the COVID-19 pandemic is still unclear, vaccines have brought great hope for the world, with several reports indicating a significant decline in the risk of COVID19-related infection and hospitalizations.


Subject(s)
COVID-19/prevention & control , SARS-CoV-2/immunology , Vaccination , COVID-19/epidemiology , COVID-19/immunology , COVID-19/virology , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/immunology , COVID-19 Vaccines/supply & distribution , Global Health , Humans , Immunocompromised Host , Mutation , SARS-CoV-2/genetics , Vaccination/adverse effects , Vaccination/psychology , Vaccination Hesitancy , Vaccine Efficacy
9.
Infect Dis Model ; 7(1): 62-81, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1536589

ABSTRACT

BACKGROUND: Besides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates, the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates. In this article, a mathematical model study has been done on the importance of vaccination and vaccine efficiency rate during an ongoing pandemic. METHODS: We simulated a five compartment mathematical model to analyze the pandemic scenario in both California, and whole U.S. We considered four vaccines, Pfizer (95%), Moderna (94%), AstraZeneca (79%), and Johnson & Johnson (72%), which are being used rigorously to control the SARS-CoV-2 pandemic, in addition with two special cases: a vaccine with 100% efficacy rate and no vaccine under use. SARS-CoV-2 related data of California, and U.S. were used in this study. FINDINGS: Both the infection and death rates are very high in California. Our model suggests that the pandemic situation in California will be under control in the last quartile of the year 2023 if vaccination program is continued with the Pfizer vaccine. During this time, six waves may happen from the beginning of the immunization where the case fatality and recovery rates will be 1.697% and 98.30%, respectively. However, according to the considered model, this period might be extended to the mid of 2024 when vaccines with lower efficacy rates are used. On the other hand, the daily cases and deaths in the U.S. will be under control at the end of 2026 with multiple waves. Although the number of susceptible people will fall down to none in the beginning of 2027, there is less chance to stop the vaccination program if vaccinated with a vaccine other than a 100% effective vaccine or Pfizer, and at that case vaccination program must run till the mid of 2028. According to this study, the unconfirmed-infectious and infected cases will be under control at the end of 2027 and at the mid of 2028, respectively. INTERPRETATION: The more effective a vaccine is, the less people suffer from this malign infection. Vaccines which are less than 90% effective do not have notable contribution to control the pandemic besides hard immunity. Furthermore, specific groups of people are getting prioritized initially, mass vaccination and quick responses are required to control the spread of this disease.

10.
J Int Med Res ; 49(5): 3000605211013550, 2021 May.
Article in English | MEDLINE | ID: covidwho-1226829

ABSTRACT

OBJECTIVE: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. METHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. RESULTS: Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04-0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group. CONCLUSIONS: Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04523831. DATA REPOSITORY ID: Dryad. doi:10.5061/dryad.qjq2bvqf6.


Subject(s)
COVID-19 , Ivermectin , Adult , Doxycycline/therapeutic use , Female , Humans , Ivermectin/therapeutic use , Male , SARS-CoV-2 , Treatment Outcome
11.
Adv Exp Med Biol ; 1318: 891-910, 2021.
Article in English | MEDLINE | ID: covidwho-1222753

ABSTRACT

This chapter briefly describes the universal intricacies caused by the COVID-19 pandemic, from the ineffectiveness of distance measures, the massive economic impacts, and the severe mental health challenges to the failure of finding a vaccine, a therapeutic agent or even accurately diagnosing the infection. The entire world is suffering, but every country is trying to combat this pandemic individually, and this deed is the main barrier that prevents reaching a peaceful end.


Subject(s)
COVID-19 , Pandemics , Humans , Mental Health , SARS-CoV-2
12.
Gene Rep ; 23: 101200, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1220851

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) is a rapidly emerging and highly transmissible disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Understanding the microbiomes associated with the upper respiratory tract infection (URTI), chronic obstructive pulmonary disease (COPD) and COVID-19 diseases has clinical interest. We hypothesize that microbiome diversity and composition, and their genomic features are associated with different pathological conditions of these human respiratory tract diseases. To test this hypothesis, we analyzed 21 RNASeq metagenomic data including eleven COVID-19 (BD = 6 and China = 5), six COPD (UK = 6) and four URTI (USA = 4) samples to unravel the microbiome diversity and related genomic metabolic functions. The metagenomic data mapped to 534 bacterial, 60 archaeal and 61 viral genomes with distinct variation in the microbiome composition across the samples (COVID-19 > COPD > URTI). Notably, 94.57%, 80.0% and 24.59% bacterial, archaeal and viral genera shared between the COVID-19 and non-COVID samples, respectively. However, the COVID-19 related samples had sole association with 16 viral genera other than SARS-CoV-2. Strain-level virome profiling revealed 660 and 729 strains in COVID-19 and non-COVID samples, respectively, and of them 34.50% strains shared between the conditions. Functional annotation of the metagenomic data identified the association of several biochemical pathways related to basic metabolism (amino acid and energy), ABC transporters, membrane transport, virulence, disease and defense, regulation of virulence, programmed cell death, and primary immunodeficiency. We also detected 30 functional gene groups/classes associated with resistance to antibiotics and toxic compounds (RATC) in both COVID-19 and non-COVID microbiomes. Furthermore, we detected comparatively higher abundance of cobalt-zinc-cadmium resistance (CZCR) and multidrug resistance to efflux pumps (MREP) genes in COVID-19 metagenome. The profiles of microbiome diversity and associated microbial genomic features found in both COVID-19 and non-COVID (COPD and URTI) samples might be helpful in developing microbiome-based diagnostics and therapeutics for COVID-19 and non-COVID respiratory diseases. However, future studies might be carried out to explore the microbiome dynamics and the cross-talk between host and microbiomes employing larger volume of samples from different ethnic groups and geoclimatic conditions.

13.
PLoS One ; 16(4): e0249644, 2021.
Article in English | MEDLINE | ID: covidwho-1172879

ABSTRACT

BACKGROUND: Post-coronavirus disease (COVID-19) syndrome includes persistence of symptoms beyond viral clearance and fresh development of symptoms or exaggeration of chronic diseases within a month after initial clinical and virological cure of the disease with a viral etiology. We aimed to determine the incidence, association, and risk factors associated with development of the post-COVID-19 syndrome. METHODS: We conducted a prospective cohort study at Dhaka Medical College Hospital between June 01, 2020 and August 10, 2020. All the enrolled patients were followed up for a month after clinical improvement, which was defined according the World Health Organization and Bangladesh guidelines as normal body temperature for successive 3 days, significant improvement in respiratory symptoms (respiratory rate <25/breath/minute with no dyspnea), and oxygen saturation >93% without assisted oxygen inhalation. FINDINGS: Among the 400 recruited patients, 355 patients were analyzed. In total, 46% patients developed post-COVID-19 symptoms, with post-viral fatigue being the most prevalent symptom in 70% cases. The post-COVID-19 syndrome was associated with female gender (relative risk [RR]: 1.2, 95% confidence interval [CI]: 1.02-1.48, p = 0.03), those who required a prolonged time for clinical improvement (p<0.001), and those showing COVID-19 positivity after 14 days (RR: 1.09, 95% CI: 1.00-1.19, p<0.001) of initial positivity. Patients with severe COVID-19 at presentation developed post-COVID-19 syndrome (p = 0.02). Patients with fever (RR: 1.5, 95% CI: 1.05-2.27, p = 0.03), cough (RR: 1.36, 95% CI: 1.02-1.81, p = 0.04), respiratory distress (RR: 1.3, 95% CI: 1.4-1.56, p = 0.001), and lethargy (RR: 1.2, 95% CI: 1.06-1.35, p = 0.003) as the presenting features were associated with the development of the more susceptible to develop post COVID-19 syndrome than the others. Logistic regression analysis revealed female sex, respiratory distress, lethargy, and long duration of the disease as risk factors. CONCLUSION: Female sex, respiratory distress, lethargy, and long disease duration are critical risk factors for the development of post-COVID-19 syndrome.


Subject(s)
COVID-19 , Fatigue , SARS-CoV-2 , Tertiary Care Centers , Adult , Aged , Bangladesh/epidemiology , COVID-19/complications , COVID-19/epidemiology , COVID-19/therapy , Fatigue/epidemiology , Fatigue/etiology , Female , Humans , Male , Middle Aged , Prospective Studies , Risk Factors , Syndrome
14.
PLoS One ; 16(4): e0249252, 2021.
Article in English | MEDLINE | ID: covidwho-1171274

ABSTRACT

BACKGROUND: Globally, studies have shown conflicting results regarding the association of blood groups with SARS CoV-2 infection. OBJECTIVE: To observe the association between ABO blood groups and the presentation and outcomes of confirmed COVID-19 cases. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study of patients with mild-to-moderately severe COVID-19 infections who presented in the COVID-19 unit of Dhaka Medical College Hospital and were enrolled between 01 June and 25 August, 2020. Patients were followed up for at least 30 days after disease onset. We grouped participants with A-positive and A-negative blood groups into group I and participants with other blood groups into group II. RESULTS: The cohort included 438 patients; 52 patients were lost to follow-up, five died, and 381 completed the study. The prevalence of blood group A [144 (32.9%)] was significantly higher among COVID-19 patients than in the general population (p < 0.001). The presenting age [mean (SD)] of group I [42.1 (14.5)] was higher than that of group II [38.8 (12.4), p = 0.014]. Sex (p = 0.23) and co-morbidity (hypertension, p = 0.34; diabetes, p = 0.13) did not differ between the patients in groups I and II. No differences were observed regarding important presenting symptoms, including fever (p = 0.72), cough (p = 0.69), and respiratory distress (p = 0.09). There was no significant difference in the median duration of symptoms in the two group (12 days), and conversion to the next level of severity was observed in 26 (20.6%) and 36 patients (13.8%) in group I and II, respectively. However, persistent positivity of RT-PCR at 14 days of initial positivity was more frequent among the patients in group I [24 (19%)] than among those in group II [29 (11.1%)]. CONCLUSIONS: The prevalence of blood group A was higher among COVID-19 patients. Although ABO blood groups were not associated with the presentation or recovery period of COVID-19, patients with blood group A had delayed seroconversion.


Subject(s)
ABO Blood-Group System/blood , COVID-19/blood , COVID-19/mortality , Hospitals, Special , SARS-CoV-2/metabolism , Adult , Bangladesh/epidemiology , COVID-19/therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Survival Rate
15.
J Transl Med ; 19(1): 32, 2021 01 07.
Article in English | MEDLINE | ID: covidwho-1015879

ABSTRACT

BACKGROUND: Although it is becoming evident that individual's immune system has a decisive influence on SARS-CoV-2 disease progression, pathogenesis is largely unknown. In this study, we aimed to profile the host transcriptome of COVID-19 patients from nasopharyngeal samples along with virus genomic features isolated from respective host, and a comparative analyses of differential host responses in various SARS-CoV-2 infection systems. RESULTS: Unique and rare missense mutations in 3C-like protease observed in all of our reported isolates. Functional enrichment analyses exhibited that the host induced responses are mediated by innate immunity, interferon, and cytokine stimulation. Surprisingly, induction of apoptosis, phagosome, antigen presentation, hypoxia response was lacking within these patients. Upregulation of immune and cytokine signaling genes such as CCL4, TNFA, IL6, IL1A, CCL2, CXCL2, IFN, and CCR1 were observed in lungs. Lungs lacked the overexpression of ACE2 as suspected, however, high ACE2 but low DPP4 expression was observed in nasopharyngeal cells. Interestingly, directly or indirectly, viral proteins specially non-structural protein mediated overexpression of integrins such as ITGAV, ITGA6, ITGB7, ITGB3, ITGA2B, ITGA5, ITGA6, ITGA9, ITGA4, ITGAE, and ITGA8 in lungs compared to nasopharyngeal samples suggesting the possible way of enhanced invasion. Furthermore, we found comparatively highly expressed transcription factors such as CBP, CEBP, NFAT, ATF3, GATA6, HDAC2, TCF12 which have pivotal roles in lung injury. CONCLUSIONS: Even though this study incorporates a limited number of cases, our data will provide valuable insights in developing potential studies to elucidate the differential host responses on the viral pathogenesis in COVID-19, and incorporation of further data will enrich the search of an effective therapeutics.


Subject(s)
COVID-19/genetics , COVID-19/immunology , Host Microbial Interactions/genetics , Host Microbial Interactions/immunology , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Adult , Aged, 80 and over , COVID-19/virology , Coronavirus 3C Proteases/genetics , Coronavirus 3C Proteases/immunology , Cytokines/genetics , Female , Genetic Variation , Humans , Immunity, Innate/genetics , Integrins/genetics , Lung/immunology , Male , Middle Aged , Models, Immunological , Mutation, Missense , Nasopharynx/immunology , Nasopharynx/virology , Pandemics , RNA-Seq , SARS-CoV-2/isolation & purification , Signal Transduction/genetics , Signal Transduction/immunology , Transcriptome , Translational Research, Biomedical
16.
Infect Genet Evol ; 87: 104670, 2021 01.
Article in English | MEDLINE | ID: covidwho-959997

ABSTRACT

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causing agent of Coronavirus Disease-2019 (COVID-19), is likely to be originated from bat and transmitted through intermediate hosts. However, the immediate source species of SARS-CoV-2 have not yet been confirmed. Here, we used diversity analysis of the angiotensin I converting enzyme 2 (ACE2) that serves as cellular receptor for SARS-CoV-2 and transmembrane protease serine 2 (TMPRSS2), which has been proved to be utilized by SARS-CoV-2 for spike protein priming. We also simulated the structure of receptor-binding domain of SARS-CoV-2 spike protein (SARS-CoV-2S RBD) with the ACE2s to investigate their binding affinity to determine the potential intermediate animal hosts that could spread the SARS-CoV-2 to humans in South Asia. We identified cow, buffalo, goat and sheep, which are predominant species in the household farming system in South Asia that can potentially be infected by SARS-CoV-2. All the bird species studied along with rat and mouse were considered less potential to interact with SARS-CoV-2. The interaction interfaces of SARS-CoV-2S RBD and ACE2 protein complex suggests pangolin as a potential intermediate host in SARS-CoV-2. Our results provide a valuable resource for the identification of potential hosts for SARS-CoV-2 in South Asia and henceforth reduce the opportunity for a future outbreak of COVID-19.


Subject(s)
COVID-19/transmission , Disease Vectors/classification , Angiotensin-Converting Enzyme 2/genetics , Animals , Asia/epidemiology , COVID-19/epidemiology , COVID-19/virology , Humans , Phylogeny , SARS-CoV-2/isolation & purification , Serine Endopeptidases/genetics , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL